Aurobindo Pharma M. R. Kumar appointed
Aurobindo Pharma (AUROPHARMA) said M. The company is valued at about ₹98,102 crore.
What happened
Aurobindo Pharma (AUROPHARMA) told the exchanges on 4 November 2026 at 08:38 PM that M. R. Kumar has been appointed.
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹98,102 crore.
The stock last traded at ₹1,705, against a 52-week range of ₹1,106–₹1,740 (2.0% below the high).
Before this filing the shares had moved +1.1% over the month and +6.8% over three months. Average daily turnover over the last 20 sessions was about ₹137 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
BCEIE has no earlier management change filing from this company on record since May 2026.
Across 123 similar disclosures by other Healthcare companies, shares moved +1.1% on average the next day and +1.8% over five days; 50% of them rose the next day.
Market-wide, 4,282 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 4 November 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.